Potential and Pitfalls of Therapy with α-Particles

Because of the short path length in tissues (<100 μm) and the high linear energy transfer (~100 keV/μm), α-particle therapy offers the potential for specific tumor cell killing with a low level of damage to surrounding tissues (*1*). Clinical applications for which this approach is favorable include minimum residual tumor tissue (*2,3*) and local–regional administration settings (*4*) as well as targeting of tumor vasculature. Because of the geometry of tumor cell populations, radiation with short ranges in tissue should be desirable because a larger fraction of decay energy would be deposited in small lesions (*5*).

Several α-emitters have been proposed in the literature. ^{211}At has many attractive features for targeted α-particle radiotherapy. ^{211}At can be produced by the cyclotron bombardment of natural bismuth with α-particles [^{209}Bi(α,2n) ^{211}At]. ^{211}At has a half-life of 7.2 h, which is long enough to permit complex labeling strategies and which could allow the delivery of therapeutic radiopharmaceuticals at sites distant from the production site. The half-life is also well matched to the pharmacokinetics of a variety of molecular entities, including peptides, monoclonal antibody fragments, and small molecules. α-Particle emission is associated with each decay of ^{211}At either by direct α-emission to ^{207}Bi (42% of decays) or by electron capture decay to ^{211}Po, with a 520-ms half-life, followed by α-emission (58% of decays). Although it is possible that this second decay mode would release radioactivity from its binding site, as the half-life of ^{211}Po is only 520 ms, the

distance traveled by the resulting polonium is likely to be low. This property is unlike that of other α-emitting radionuclides, such as ^{212}Pb, for which the distance traveled by the daughter nuclide is likely to be significant (*6,7*). Liposomes have been developed to minimize the escape of daughter nuclides from the site of the initial decay (*8*).

A consequence of electron capture decay is that 77- to 92-keV photons from the excited polonium daughter nucleus are emitted and can be imaged by either planar or SPECT scanners (*9,10*). Several research groups have developed techniques for attaching ^{211}At to a wide variety of targeting molecules (*11–14*). The toxicity of ^{211}At for human cancer cells has been demonstrated with a wide variety of ^{211}At-labeled compounds in cell cultures (*15–18*) and in animal models (*19–21*). A clinical trial has been initiated at Duke University with ^{211}At-labeled monoclonal antibodies (*22,23*), and other trials are in the planning stage. On pages 1393–1400 of this issue of *The Journal of Nuclear Medicine,* Pozzi and Zalutsky (*24*) report the results of important basic science studies on the radiolytic effects of astatine α-particles on the synthesis of an important ^{211}At-labeled precursor.

With the interest in the production of high yields of short–half-life positron-emitting radiopharmaceuticals as well as high yields of therapeutic radiopharmaceuticals, studies on radiolytic effects are becoming more important. This topic has been of interest to radiochemists for many years (*25*). Recently, several publications addressed the stability of positron-emitting radiopharmaceuticals, particularly those labeled with ^{11}C (*26–29*). Fukumura et al. (*26*) carefully examined the stability of 14 ^{11}C-labeled radiopharmaceuticals and examined the effects of radical scavengers on stability. Interestingly, they showed that, depending

on the chemical structure of the ^{11}C-labeled radiopharmaceutical, different scavengers had different efficacies. By using appropriate additives according to the class of the radiopharmaceutical, they showed that it is possible to prepare ^{11}C-labeled radiopharmaceuticals with high radiochemical purity even at high levels of radioactivity.

In the article in this issue (*24*) and in an earlier article (*30*), Pozzi and Zalutsky carefully evaluated the effects of solvents on the radiolysis of precursors as well as the effects of increasing amounts of activity on radiation effects in astatine-labeled radiopharmaceuticals. In their first article (*30*), Pozzi and Zalutsky incubated *N*-succinimidyl 3-(tri-*n*-butylstannyl)benzoate and *N*-succinimidyl 3-(trimethylstannyl)benzoate with various astatine time–activity combinations. They used various solvents—chloroform, methanol, and benzene—and varied the pH. Extensive radiolytic decomposition of both *N*-succinimidyl 3-(tri-*n*-butylstannyl)benzoate and *N*-succinimidyl 3-(trimethylstannyl)benzoate was observed in chloroform, but a greater degree of stability was observed in both methanol and benzene. Their conclusion was that the nature of the solvent profoundly influences the ability to synthesize high levels of *N*-succinimidyl 3-^{211}At-astatobenzoate (SAB) and possibly other ^{211}At-labeled radiopharmaceuticals.

In their second article (this issue) (*24*), Pozzi and Zalutsky extended this work by examining the yields of SAB as a function of the radiation dose. They found that SAB production declined rapidly with increasing radiation dose. However, surprisingly, they obtained greater than 30% yields of SAB when the reaction was carried out with methanol but without the addition of acetic acid, an oxidant agent previously considered to be essential for astatodestannylation. Their conclusion that radiolytic effects play an impor-

tant role in the synthesis of therapeutic amounts of astatine-labeled radiopharmaceuticals is an important observation and suggests that basic research is needed to evaluate reaction conditions that are not affected by radiolysis. Such research is essential for an understanding of the role of radiolysis in the preparation of high levels of astatine-labeled radiopharmaceuticals. These studies must be performed in a timely manner because of the great promise of [211]At-labeled radiopharmaceuticals for therapeutic applications.

Michael J. Welch, PhD
Washington University School of Medicine
St. Louis, Missouri

REFERENCES

1. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. *J Nucl Med.* 2005;46(suppl):199S–204S.
2. Sautter-Bihl M-L, Herbold G, Bihl H. Minimal residual disease: a target for radioimmunotherapy with ^{131}I-labeled monoclonal antibodies? Some dosimetric considerations. *Recent Results Cancer Res.* 1996;141:67–75.
3. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. *Cancer Immunol Immunother.* 2003;52:281–296.
4. Akabani G, Hawkins WG, Eckblade MB, Leichner PK. Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution. *J Nucl Med.* 1997; 38:308–314.
5. Zalutsky, M. Radionuclide therapy. In: *Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences.* Dordrecht, The Netherlands: Kluwer Academic; 2003. Roesch F, ed. *Handbook of Nuclear Chemistry;* vol 4:315–348.
6. Kennel SJ, Chappell LL, Dadachova K, et al. Evaluation of [225]Ac for vascular targeted radioimmunotherapy of lung tumors. *Cancer Biother Radiopharm.* 2000;15:235–244.

7. Mirzadeh S, Kumar K, Gansow OA. The chemical fate of [212]Bi-DOTA formed by beta-decay of [212]Pb-(DOTA)$_2$. *Radiochim Acta.* 1993;60:1–10.
8. Henriksen G, Schoultz BW, Hoff P, Larsen RH. Potential in vivo generator for alpha-particle therapy with [212]Bi: presentation of a system to minimize escape of daughter nuclei decay of [212]Pb to [212]Bi. *Radiochim Acta.* 2003;91:109–114.
9. Turkington TG, Zalutsky MR, Jaszczak RJ, et al. Measuring astatine-211 distributions with SPECT. *Phys Med Biol.* 1993;38:1121–1130.
10. Johnson EL, Turkington TG, Jaszczak RJ, et al. Quantitation of [211]At in small volumes for evaluation of targeted radiotherapy in animal models. *Nucl Med Biol.* 1995;22:45–54.
11. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. *Curr Pharm Des.* 2000;6:1433–1455.
12. Wilbur DS, Vessella RL, Stray JE, et al. Preparation and evaluation of para-[[211]At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab′)$_2$: in vivo distribution comparison with para-[^{125}I]iodobenzoyl labeled A6H F(ab′)$_2$. *Nucl Med Biol.* 1993;20:917–927.
13. Wilbur DS, Chyan MK, Hamlin DK, et al. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nidocarboranyl compounds. *Bioconjug Chem.* 2004;15: 203–223.
14. Link EM. Targeting melanoma with [211]At/^{131}I-methylene blue: preclinical and clinical experience. *Hybridoma.* 1999;18:77–82.
15. Larsen RH, Vaidyanathan G, Zalutsky MR. Cytotoxicity of alpha-particle emitting 5-[[211]At]astato-2′-deoxyuridine in human cancer cells. *Int J Radiat Biol.* 1997;72:79–90.
16. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. *Radiat Res.* 1998;149:155–162.
17. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. *Radiat Res.* 1998;150:263–268.
18. Zalutsky M, Welsh P, Akabani G, Zhao X-G. Alpha-particle emitting astatine-211 labeled herceptin is highly cytotoxic for HER-2-expressing breast cancer cells in vitro [abstract]. *Proc Am Assoc Cancer Res.* 2002;43:481.

19. Larsen RH, Bruland OS. Intratumour injection of immunoglobulins labeled with the alpha-particle emitter [211]At: analyses of tumour retention, microdistribution and growth delay. *Br J Cancer.* 1998; 77:1115–1122.
20. Garg PK, Harrison CL, Zalutsky MR. Comparative tissue distribution in mice of the alpha-emitter [211]At and ^{131}I as labels of a monoclonal antibody and F(ab′)$_2$ fragment. *Cancer Res.* 1990;50:3514–3520.
21. Andersson H, Palm S, Lindegren S, et al. Comparison of the therapeutic efficacy of [211]At- and ^{131}I-labeled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. *Anticancer Res.* 2001;21:409–412.
22. Zalutsky M, Reardon D, Akabani G, et al. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: phase I study [abstract]. *Neuro-Oncology.* 2002; 4(suppl):S103.
23. Zalutsky MR. Targeted radiotherapy of brain tumours. *Br J Cancer.* 2004;90:1469–1473.
24. Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 2: radiolytic effects of [211]At α-particles influence *N*-succinimidyl 3-[211]At-astatobenzoate synthesis. *J Nucl Med.* 2005;46:1393–1400.
25. Bayly RJ, Evans EA. Stability and storage of compounds labeled with radioisotopes. *J Labelled Compd.* 1966;2:1–34.
26. Fukumura T, Nakao R, Yamaguchi M, Suzuki K. Stability of ^{11}C-labeled PET radiopharmaceuticals. *Appl Radiat Isot.* 2004;61:1279–1287.
27. Bogni A, Bombardieri E, Iwata R, Cadini L, Pascali C. Stability of L-[*S*-methyl-^{11}C]methionine solutions. *J Radioanal Nucl Chem.* 2003;256:199–203.
28. Fukumura T, Akaike S, Yoshida Y, Suzuki K. Decomposition of an aqueous solution of [^{11}C]Ro 15–4513: implication of hydrated electrons in the radiolysis of [^{11}C]Ro 15–4513. *Nucl Med Biol.* 2004;30:389–395.
29. Fukumura T, Yamaguchi M, Suzuki K. Radiolysis of aqueous [^{11}C]iomazenil solution. *Radiochim Acta.* 2004;92:119–123.
30. Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by [211]At α-particles. *J Nucl Med.* 2005;46:700–706.